Entero Healthcare Solutions Limited — Investor Meet, 19-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Financial Performance: In Q3 FY '25, Entero Healthcare reported consolidated revenue of INR 1,359 crores, marking a 37% increase year-over-year, with 17% attributed to organic growth and 20% from acquisitions. Gross profit reached INR 133 crores, resulting in a gross margin of 9.8%, an increase from 9.1%. EBITDA grew 75% year-on-year to INR 50 crores, reflecting an EBITDA margin improvement from 2.9% to 3.7%. Profit after tax soared over fourfold to INR 29 crores, driven by higher EBITDA and optimized finance costs.

Future Outlook and Growth Drivers: Management emphasized a dual strategy of organic and inorganic growth to capture a share of the $33 billion healthcare distribution market in India. The focus is on expanding into new geographies and product categories, while strengthening presence in Tier 2 and Tier 3 cities. The company aims to grow its organic business at 1.5x to 2x the Indian Pharmaceutical Market growth rate.

Order Book and Operational Updates: To date in FY '25, Entero has completed 10 acquisitions contributing INR 792 crores in annualized revenue. The management expects to pursue additional acquisitions to further broaden their geographical reach and product offerings.

Analyst Q&A Insights: Analysts probed revenue projections and operational challenges such as supply chain management. Management maintained confidence in a positive trajectory for operating cash flow and reiterated the significance of acquisitions as a growth driver.

Market or Regulatory Updates: The management noted no substantial changes in the competitive landscape that could impact their acquisition strategy, highlighting a favorable buyer-to-seller ratio.

Strategic Focus Areas: Key themes include enhancing operational efficiency through technology, leveraging acquisitions for scale, and diversifying product offerings, underlining Entero's commitment to long-term growth.

Investor Insight: Entero's financial performance and growth strategies appear to support a ‘buy’ position, underpinned by significant revenue growth and margin improvements, despite operational challenges and cash flow concerns. The proactive acquisition strategy and market positioning contribute to a positive outlook.